The nerve growth factor receptor (NGFR/p75) is a potential tumor suppressor, but its role in colorectal cancer is unknown. Here, the hypermethylation status, biologic function, and clinical relevance were determined for p75NGFR in colorectal cancer. The methylation status and expression of p75NGFR were assessed in colorectal cancer cell lines and clinical tissues by bisulfite genomic sequencing (BGS), qRT-PCR, and immunoblot assay. Methylation of p75NGFR was frequently found in colorectal cancer, leading to its silencing or downregulation, and it was effectively restored by a demethylation agent. The overexpression of p75NGFR in multiple colorectal cancer cell model systems significantly inhibited cell proliferation (concomitant with G 1 -phase arrest), invasion, and colony formation and induced cell apoptosis. In contrast, p75NGFR knockdown significantly promoted proliferative and invasive phenotypes. Importantly, p75NGFR methylation was observed in the majority of primary colorectal cancer specimens and was associated with histologic grade and preoperative serum CA19-9 levels. Multivariate analysis indicated that patients who lack p75NGFR have reduced overall survival (64% vs. 75%, P ¼ 0.028) and disease-free survival (61% vs. 72%, P ¼ 0.034) compared with p75NGFR-positive patients. In conclusion, p75NGFR is predominantly silenced or downregulated in colorectal cancer, and its biologic activities are consistent with it being a relevant tumor suppressor.
Introduction
Colorectal cancer is one of the most common malignancies of the alimentary tract, with more than 1.2 million new cases and 608,700 deaths estimated to have occurred in 2008. Colorectal cancer arises as a consequence of the accumulation of genetic and epigenetic alterations in colorectal epithelial cells during neoplastic transformation (1) . Epigenetic alteration, particularly the hypermethylation of CpG islands in the promoter regions, has been extensively studied and recognized as one of the main factors in silencing the tumor-suppressor genes, which leads to colon and rectum carcinogenesis (2, 3) . The detection of promoter methylation as a means of identifying novel tumor-suppressor genes provides us with a new method for investigating the potential molecular mechanisms involved in colon and rectum carcinogenesis and allows us to identify better approaches to diagnostic and therapeutic evaluation.
The nerve growth factor receptor (NGFR/p75), which belongs to the TNF receptor (TNFR) family, is a multifunctional cell surface receptor that exerts diverse functions, such as the stimulation of cell survival and differentiation during neuronal development (4) . The expression of p75NGFR has been observed in several human cancers, such as thyroid carcinoma, stomach cancer, and liver cancer (5) (6) (7) (8) (9) (10) . p75NGFR has different functions based on the tumor type in which it is found. For example, it has been shown to exert a tumor-promoting effect in brain tumors and melanomas (11, 12) , whereas it has also been proposed as a potential tumor suppressor in bladder (7) , stomach (9) and liver cancers (10) . However, with the exception of a previous study reporting hypermethylation of p75NGFR in the serum of patients with colorectal cancer (13) , no other studies to date have reported the methylation status, expression level, or function of p75NGFR in colorectal cancer. Therefore, we conducted this study to determine the role of p75NGFR in the initiation, progression and prognosis of colorectal cancer.
In a previous study, we conducted a genome-promoter region methylation microarray study using methylated DNA immunoprecipitation analysis (MeDIP) to screen for novel methylated CpG loci in six pairs of colorectal cancer tissue and adjacent noncancerous tissue samples. This assay indicated that p75NGFR was frequently hypermethylated compared with the paired adjacent noncancerous tissue samples, in which p75NGFR was identified as a potentially hypermethylated locus (14) . In the present study, we demonstrate that silencing of p75NGFR expression in colorectal cancer is associated with the hypermethylation of CpG islands in the promoter region and that it can be restored by the demethylating agent 5-Aza-2 0 -deoxycytidine (5-Aza). Moreover, p75NGFR reexpression in colorectal cancer cells suppressed cell proliferation and invasion through the induction of G 1 -phase arrest and cell apoptosis. Finally, the clinical implication of the role of p75NGFR in colorectal cancer was investigated. Our results indicate that p75NGFR is a candidate tumor suppressor and has independent prognostic potential in colorectal cancer.
Materials and Methods

Primary tumor tissues
Primary tumor and corresponding adjacent noncancerous tissues were obtained from patients with colorectal cancer in our hospital at the time of surgery. All samples were snap-frozen in liquid nitrogen and stored at À80 C until used. All patients in this study gave informed consent, and the study was approved by the Ethics Committee of Sun Yat-sen University in China.
Cell culture and 5-Aza treatment
Eight human colon cancer cell lines (HT29, SW480, HCT8, HCT116, LoVo, Ls174t, CaCO2, and DLD1) were obtained from the Culture Collection of the Chinese Academy of Science (Shanghai, China), cultured in RPMI-1640 medium or DMEM (Invitrogen), supplemented with 10% FBS and incubated in 5% CO 2 at 37 C. For pharmacologic demethylation, cells with methylated p75NGFR were treated with 3 mmol/L 5-Aza (Sigma) for 3 consecutive days. The culture medium was changed every 24 hours. An equivalent concentration of DMSO was used in the control group.
Methylation-specific PCR and bisulfite genomic sequencing
Genomic DNA was treated with sodium bisulfite using the Zymo DNA Modification Kit (Zymo Research) according to the protocol. Bisulfite-treated genomic DNA was then amplified using bisulfite genomic sequencing (BGS) and methylation-specific PCR (MSP) primers. Primer sequences for MSP and BGS are listed in Supplementary Table S1 . The PCR products from BGS were purified and cloned into pTA vectors (Invitrogen) for sequencing. At least five colonies were randomly chosen for plasmid extraction and sequencing.
The Cancer Genome Atlas data
Genome-wide DNA methylation and mRNA expression data for p75NGFR in tumor tissue from a total of 963 reports for 29 cancers were analyzed from The Cancer Genome Atlas (TCGA), which aims to analyze molecular profiles at the DNA, RNA, protein, and epigenetic levels for a large number of human samples from various tumor types and subtypes (http://gdac. broadinstitute.org). The correlation between mRNA expression and DNA methylation of p75NGFR in various types of cancers is analyzed, including colon adenocarcinoma.
This Methylation27, Illumina Infinium Human Methylation450, Illumina DNA Methylation OMA002, Illumina DNA Methylation OMA003 were put into the analysis software Firehose-get. Similarly, mRNA expression data from different kinds of Gene Expression Platforms, including Agilent 244K Gene Expression G4502A-07-1, Agilent 244K Gene Expression G4502A-07-2, Agilent 244K Gene Expression G4502A-07-3, Affymetrix Human Exon 1.0 ST Array, and Affymetrix HT Human Genome U133 Array of all 29 cancer types, were also put into this analysis software. The correlation of methylation and gene-expression arrays was paired on the basis of Entrez Gene ID concordance. The association between CpG site methylation and the level of expression of the corresponding genes between the two platforms was determined by calculating the correlation measure spearman. Finally, we summarize up the correlation coefficient, P and Q values of the correlation coefficient, mean detection level of gene-expression probes, mean detection level of CpG methylation probes of the correlation between mRNA expression and DNA methylation in all 29 cancer types.
Analysis of CpG island methylation phenotype
The classic CpG island methylation phenotype (CIMP) marker panel, consisting of hMLH1, p16, MINT1, MINT2, and MINT31, was analyzed using MSP. The primer sequences and PCR conditions of all five loci for both the methylated and unmethylated forms were the same as described previously (15, 16) . For each MSP reaction, placental DNA treated with M.SssI methyltransferase (New England Biolabs Inc.) or distilled water (without template DNA) was used as the positive and negative controls, respectively.
RNA extraction, RT-PCR, and quantitative real-time PCR
Total RNA was extracted from colorectal cancer tissues and cell lines using TRizol reagent (Invitrogen) according to the manufacturer's instructions. A reverse transcription reaction was performed using 1 mg of total RNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RT-PCR was carried out for p75NGFR using b-actin as an internal control. Quantitative RT-PCR (qRT-PCR) was carried out with the SYBR Green Master Mix Kit and an ABI 7500 System (Applied Biosystems) using the primers listed in Supplementary Table S1 . b-Actin levels were used for normalization.
Western blot analysis
Total protein from HT29 and DLD1 cells was extracted after 48 hours of transfection with pcDNA3.1-p75NGFR or pcDNA3.1-empty vector, and of si-p75NGFR or si-control. Protein (30 mg) from each sample was separated by 10% SDSPAGE and transferred onto an equilibrated nitrocellulose membrane (Amersham Biosciences). After incubation with the specific primary antihuman antibody (1:1,000, 1:2,000, and 1:1,500 for p75NGFR, p21, and cleaved caspase-3, respectively) or mouse anti-human GAPDH (1:4000) at 4 C overnight, secondary antibodies were applied to the membranes. After incubation with the secondary antibodies, the proteins were detected by enhanced chemiluminescence (Amersham Corporation). The primary antibodies for p75NGFR, p21 and cleaved caspase-3 were purchased from Abcam, and GAPDH was purchased from Cell Signaling Technology. Secondary antibodies were purchased from Santa Cruz Biotechnology unless otherwise indicated.
Plasmid construction and transfection
The full-length open reading frame (ORF) of p75NGFR was subcloned into the XbaI and EcoRI sites of the pcDNA3.1 mammalian expression vector to generate pcDNA3.1-p75NGFR vector. The primers used for cloning are listed in Supplementary  Table S1 . The p75NGFR overexpression plasmid or empty vector was transfected into HT29 and DLD1 cells (2 Â 10 5 cells/well of a 6-well plate) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Transfected HT29 and DLD1 cells were selected with 500 and 900 mg/mL G418 (Invitrogen), respectively. Stably transfected cells with p75NGFR expression plasmid or empty vector were maintained with 200 mg/mL of G418.
Immunohistochemical assay
Formalin-fixed, paraffin-embedded sections of tissues were subjected to immunostaining using a primary rabbit anti-human p75NGFR polyclonal antibody. Briefly, tissue sections were deparaffinized, rehydrated, and subjected to antigen retrieval by boiling in sodium citrate buffer (10 mmol/L, pH 6.0). The sections were then incubated overnight at 4 C with the primary rabbit anti-human p75NGFR antibody (1:100), washed, incubated with a biotinylated anti-rabbit IgG secondary antibody, followed by the addition of the strepavidin-biotin complex, and then the tissue was stained with 3,3-diaminobenzidine. After visualization of immunoreactivity, the sections were counterstained with hematoxylin and mounted.
siRNA knockdown of p75NGFR
Two pairs of siRNA were used to knockdown the expression of p75NGFR. The si-p75NGFR-1 (sense: 5 0 -CGAACAAGACCUCAUAGCCAdTdT-3 0 ; antisense: 5 0 -dTdT CUUGUUCUGGAGUAU-CGGU-3 0 ) and si-p75NGFR-2 (sense:5 0 -CGAGCACAUAGACUCCUUUdTdT-3 0 ; antisense: 5 0 -dTdTGCUCGUGUAUCUGAGGA-AA-3 0 ) duplexes that target the sequences of p75NGFR mRNA-1 (5 0 -GAACAAGACCTCATAGCCA-3 0 ) or p75NGFR mRNA-2 (5 0 -CGAGCACATAGACTCCTTT-3 0 ), respectively, were synthesized by Dharmacon. Transfection of siRNA was carried out using Lipofectamine 2000 (Invitrogen). Briefly, 1 day before transfection, cells were plated in 5 mL of growth medium without antibiotics. On the day of transfection, the media in a 60-mm plate were replaced with 5 mL of media without antibiotics and 1 mL of the Lipofectamine 2000-siRNA complex. Lipofectamine 2000 (5 mL) in 500 mL of Opti-Mem (Gibco) and 200 pmol/L siRNA in 500 mL of Opti-Mem were mixed together for a final volume of 1 mL of the Lipofectamine 2000-siRNA complex. The mixture was incubated in the 60-mm plate at room temperature for 15 minutes. In each 60-mm plate, the final siRNA concentration was 50 nmol/L. The cells were incubated in 5% CO 2 at 37 C for 6 hours. The media were replaced with 5 mL of media without antibiotics. The scrambled siRNA (5 0 -AATTCTCCGAACGTGTCACGT-3 0 ), which does not match any human genome sequence, was purchased from Dharmacon. Twenty-four to 48 hours after transfection, the cells were assayed for mRNA and protein expression or used in vitro assays.
Colony formation assay
HT29 and DLD1 cells (2 Â 10 5 cells/well) were plated in 12-well plates and transfected with pcDNA3.1-p75NGFR or empty vector. Two days after transfection, the cells were split at a 1:20 ratio on 6-well plates with G418. After culturing for 14 to 21 days, the cells were fixed with 70% ethanol and stained with crystal violet solution. Colonies with >50 cells per colony were counted. All experiments were conducted three times in triplicate.
Cell viability and proliferation assay
Cell viability was examined using the Vybrant MTT Cell Proliferation Assay Kit (Invitrogen) according to the manufacturer's instructions. Cell proliferation was detected using incorporation of 5-ethynyl-2 0 -deoxyuridine (EdUrd) with the Click-iT EdUrd Cell Proliferation Assay Kit (Invitrogen) following the manufacturer's instructions.
Matrigel invasion assay and Transwell migration assay
The abilities of invasion and migration of colorectal cancer cells were evaluated using a BD BioCoat Growth Factor Reduced Matrigel Invasion Chamber and a Transwell Migration Chamber (BD Biosciences) according to the manufacturer's instructions. Complete culture medium (supplemented with 20% FBS) was used as a chemoattractant. The insert membranes were stained with DAPI, and the permeating cells were counted under an inverted microscope and photographed.
Cell-cycle and apoptosis assay
HT29 and DLD1 cells stably transfected with pcDNA3.1-P75NGFR or pcDNA3.1 empty vector were fixed in 70% ethanol and stained with 50 mg/mL propidium iodide (BD Pharmingen). The cells were then sorted by FACSCalibur (BD Biosciences), and the cell-cycle profiles were analyzed using the ModFit 3.0 software (Verity Software House). Apoptosis was determined by dual staining with Annexin V-FITC and propidium iodide (Invitrogen). The Annexin V-positive cells were counted as apoptotic cells. A Western blot analysis was used to detect the p21 and cleaved caspase-3 protein levels to confirm the results of the flow cytometry.
Statistical analysis
Statistical analysis was performed using the SPSS statistical package (version 16.0; SPSS). The c 2 test or Fisher exact test was used to compare the association between clinicopathologic characteristics and the p75NGFR methylation status. Quantitative data were expressed as the mean AE SD and compared using the Student t test between the various groups. The effect of p75NGFR on survival was performed using the Kaplan-Meier method and compared using the log-rank test. Overall survival (OS) was defined as the time from the date of surgery to the date of death from any causes, and disease-free survival (DFS) was defined as the time from the date of surgery to the date of recurrence or death, whichever came first. A multivariate analysis of the factors that influenced survival was performed using the Cox proportional hazards regression model. All analyses were two-sided, and a P value of <0.05 was considered to be statistically significant.
Results
Methylation status of the p75NGFR gene in human colorectal cancer tissues and cell lines
As described in a previous report and our preliminary study (13, 14) , p75NGFR was considered to be one of the highly methylated genes in colorectal cancer. To validate these results, a 418-bp fragment located at 44928023-44928440 of NM_002507 (NCBI accession number) and spanning intron 1 of the p75NGFR gene was identified, and primers for MSP and BGS were designed in the region of exon 1 to detect the methylation status of the p75NGFR gene (Fig. 1A) . MSP was subsequently carried out to analyze the methylation status of the p75NGFR gene in colorectal cancer samples and cell lines. In an independent set of 38 samples, MSP analysis indicated that p75NGFR was aberrantly methylated in 7.9% (3/38) of normal colon mucosa and 60.5% (23/38) of adenocarcinomas (normal mucosa vs. adenocarcinomas; P < 0.001, Supplementary Fig. S1 ). Among the colorectal cancer cell lines, complete promoter methylation of p75NGFR was found in six cell lines (HT29, HCT8, LoVo, Ls174t, CaCO2, and DLD1), partial methylation was found in HCT116 cells, and nonmethylation was observed in the SW480 cell line. The results of BGS were consistent with those of MSP. Representative data are shown in Fig. 1B-D. Transcriptional silencing of p75NGFR is associated with promoter methylation in colorectal cancer cell lines and tissues qRT-PCR was performed to determine whether methylation led to p75NGFR transcriptional silencing. A 122-bp transcript corresponding to the p75NGFR gene was detected in the SW480 and HCT116 cell lines, whereas no transcript was detected in the six completely methylated cell lines (HT29, HCT8, LoVo, Ls174t, CaCO2, and DLD1). In combination with the MSP and BGS results, the qRT-PCR results indicate that p75NGFR was frequently silenced in the methylated cell lines but was not silenced in either the partially methylated HCT116 or unmethylated SW480 cells ( Fig. 2A) . To further confirm the epigenetic silencing of p75NGFR in the colorectal cancer cell lines, three of the methylated cell lines that exhibit silencing of p75NGFR (HT29, DLD1, and Ls174t) were treated with the demethylating agent 5-Aza. Expression of p75NGFR was restored and increased by 2.92 AE 0.14-, 1.58 AE 0.14-, and 6.56 AE 0.40-fold compared with the control group in the three cell lines, respectively, upon 5-Aza treatment ( Fig. 2A) .
The mRNA expression level of p75NGFR in human colorectal cancer tissues was also examined. In another independent set of 32 patients, lower levels of p75NGFR mRNA were detected in colorectal cancer tissues compared with the corresponding adjacent noncancerous tissues (P ¼ 0.004), which was consistent with the MSP results indicating the higher methylation of p75NGFR in cancerous tissues compared with noncancerous tissues in colorectal cancer. Representative data are shown in Fig. 2B .
To explore the effect of methylation on p75NGFR protein expression, MSP and immunohistochemistry of the p75NGFR protein were performed on 128 primary colorectal cancer samples. p75NGFR protein expression was either completely lost or was present in more than 50% of the colorectal cancer cells per sample. Representative data are shown in Fig. 2C . On the basis of p75NGFR protein expression level, the patients with colorectal cancer were divided into p75NGFR-positive and p75NGFR-negative groups. More p75NGFR-negative samples were found in colorectal cancer tissues with p75NGFR methylation than in those with no p75NGFR methylation (84.5% vs. 36.4%, P < 0.001, Table 1 ). p75NGFR is inactivated by promoter hypermethylation in colorectal cancer. A, silencing of p75NGFR by promoter methylation was observed in DLD1, HCT8, HT29, CaCO2, Ls147t, and SW1116 cells, but not in the HCT116 and SW480 cell lines (top). p75NGFR expression was restored in Ls147t, HT29, and DLD1 cells after treatment with 5-Aza (bottom). The methylation status and mRNA expression level of p75NGFR were detected by MSP/UMP and qRT-PCR, respectively. mRNA expression levels were normalized to b-actin, which served as a control for the input cDNA. B, the methylation status and mRNA expression of p75NGFR in human colorectal cancer samples. Representative results of the methylation status of p75NGFR in the colorectal cancer samples are shown in the top. mRNA expression of p75NGFR in the colorectal cancer samples (middle) and the expression levels of p75NGFR in tumor tissues were significantly lower than those observed in normal tissues (bottom). N, normal tissue; T, tumor tissue; C1, genomic DNA from placental tissue treated with SssI methylase or untreated was used as positive control for MSP or UMP, respectively; C2, genomic DNA from colorectal cancer tissue (not bisulfite-treated) was used as negative control for MSP or UMP. C, immunohistochemical staining of p75NGFR protein in colorectal cancer samples. Primary rabbit anti-human p75NGFR antibody (1:100) was used to detect protein expression. Representative images from IHC of p75NGFR in methylation/p75NGFR-negative colorectal cancer samples (right), unmethylated/p75NGFR-positive (middle), and normal mucosa (left).
Epigenetic silencing of p75NGFR involved in certain types of solid cancers
In our efforts to confirm epigenetic silencing of p75NGFR in other types of solid cancers, an overview analysis from the TCGA data portal was released in the Firehose analysis run "January 15, 2014," in which a total of 963 reports for 29 cancers are available (http://gdac.broadinstitute.org/runs/analyses__latest/reports/). In these pipelines, the correlation between mRNA expression and DNA methylation in cancers, including colon adenocarcinoma, is analyzed. On the basis of the analyzed data, p75NGFR was identified as one of significantly negatively correlated genes (correlation coefficient: À0.33; Q value: 3.2 Â 10 À8 ) in colon cancer, which supports the results indicating the epigenetic silencing of p75NGFR in colorectal cancer in the present study. In addition, we further explored the correlation between methylation status and mRNA expression of p75NGFR in other cancers. Among 29 cancers, with the exception of colon cancer, colorectal cancer, and rectal cancer, a significant negative correlation was also found in 22 cancers (Supplementary Table S2 ), but not in five other cancers, including adrenocortical carcinoma, bladder urothelial carcinoma, cervical squamous cell carcinoma, and endocervical adenocarcinoma, ovarian serous cystadenocarcinoma and sarcoma. No study on the gene methylation status for esophageal carcinoma and the pan-cancer cohort with 12 disease types is provided. Meanwhile, one of the methylation probes in our analysis is same to those for TCGA database ( Supplementary  Fig. S2 ). Taken together, these results indicate that epigenetic silencing of p75NGFR is involved in certain types of solid cancers, including colorectal cancer.
Frequency of methylation at markers using classic CIMP panels and its relationship with p75NGFR methylation status in colorectal cancer We determined the CIMP at five loci in a series of 32 patients with colorectal cancer. Methylation of the Mint1 and Mint2 loci was observed in a high proportion of the studied colorectal cancers (62.5% and 56.3%, respectively). In addition, p16, hMLH1, and Mint31 were methylated in 34.4%, 18.8%, and 15.6% of the cases, respectively. Using these five loci that were preferentially methylated in colorectal cancer cases, we determined the percentage of patients with or without p75NGFR methylation having methylation at 0, 1, 2, 3, 4, or 5 loci (Supplementary Fig. S3 and Table S3 ). When patients were categorized as CIMP (À) having either 0 to 2 loci methylated, or CIMP (þ) with 3 to 5 loci methylated, the Fisher exact test showed no statistically significant association of the CIMP status with the p75NGFR methylation status (Supplementary Table S4 , P ¼ 1.000).
P75NGFR inhibits colorectal cancer cell growth
The frequent silencing or downregulation of p75NGFR in colorectal cancer cell lines and tissues suggests that it is a potential tumor-suppressor gene in colorectal cancer. To validate this hypothesis, DLD1 and HT29 cells overexpressing p75NGFR were established. The expression level of p75NGFR was determined by qRT-PCR and Western blot analysis (p75NGFR in mRNA level was increased by 95.83 AE 3.49-fold in DLD1 cells and 31.81 AE 0.63-fold in HT29 cells, respectively, Fig. 3A) . The overexpression of p75NGFR significantly suppressed the cell growth of both DLD1 (P < 0.01) and HT29 (P < 0.001) cells, as determined by an MTT assay (Fig. 3B) . This inhibitory effect was confirmed using an EdUrd cell proliferation assay. The proliferation of p75NGFR-transfected cells significantly decreased to 70% in DLD1 cells (P < 0.01) and 65% in HT29 cells (P < 0.01) compared with the control groups (Fig. 3C) . Moreover, colony formation assays demonstrated that p75NGFR transfectants had a dramatic reduction in the number of colonies in DLD1 cells (down to 54%, P < 0.01) and HT29 cells (down to 38%, P < 0.001, Fig. 3D ) compared with the control groups.
To investigate the effects of p75NGFR on cancer cell migratory and invasive abilities, the Matrigel invasion assay and Transwell migration assay were performed. The overexpression of p75NGFR markedly decreased cell invasion in p75NGFR-transfected DLD1 and HT29 cells (down to 36% and 41%, respectively, P < 0.01, Fig.  3E ). In addition, p75NGFR significantly impaired the cell migration of both DLD1 and HT29 cells (down to 44% and 38%, respectively, P < 0.01, Fig. 3F ). These results indicate that p75NGFR plays an important inhibitory role in the invasion of cancer cells.
To further validate the inhibitory effect of p75NGFR on cell proliferation and invasion, p75NGFR expression was silenced by siRNA in SW480 cells (down to 56.5% for si-p75NGFR-1 and 61.7% for si-p75NGFR-2, P < 0.01, Fig. 4A ), which normally highly express p75NGFR. Knockdown of p75NGFR expression significantly increased cell invasion (upregulated 4.54 AE 1.08-fold, P < 0.001) and migration abilities (upregulated 2.24 AE 0.46-fold, P < 0.001, Fig. 4B ) compared with the control groups. Similarly, knockdown of p75NGFR also significantly promoted the cell growth and proliferation ability (upregulated 1.73 AE 0.11-fold, P < 0.05, Fig. 4C ). These results provide further evidence indicating a role of p75NGFR as a tumor suppressor in colorectal cancer.
Overexpression of p75NGFR induces cell-cycle arrest and apoptosis
To determine the underlying molecular mechanism by which p75NGFR inhibited cell growth, we analyzed the effect of p75NGFR on cell-cycle distribution by flow cytometry after propidium iodide staining. The ectopic expression of p75NGFR led to a significant increase in the number of G 1 -phase HT29 cells (65.78% AE 0.59% vs. 61.34% AE 1.10%, P < 0.05, Fig. 5A ) and DLD1 cells (70.40% AE 1.00% vs. 64.35% AE 1.61%, P < 0.05, Fig. 5B ) compared with the control groups. Concomitant with this increase, there was a significant decrease in the number of cells accumulating in the G 2 -phase (6.54% AE 0.46% vs. 8.98% AE 0.20%, P < 0.05, Fig. 5A ) for HT29 cells and in the S-phase (20.89% AE 0.40% vs. 25.12% AE 0.65%, P < 0.05, Fig. 5B ) for DLD1 cells. An induction of cell-cycle arrest was also indicated by the enhanced expression of p21, one of the CDKIs, in p75NGFR-transfected cells (Fig. 5C ). These results indicate that the overexpression of p75NGFR inhibits cell growth by suppressing cell proliferation ability and inducing G 1 -phase arrest. To examine the contribution of apoptosis to the observed growth inhibition of p75NGFR-transfected cells, we carried out flow cytometry with Annexin V-FITC and propidium iodide staining. Increases in both early and late apoptosis were observed in p75NGFR-transfected cells compared with the control groups in both HT29 (7.10% AE 0.10% vs. 4.56% AE 0.31%, P < 0.01 and 9.93% AE 1.14% vs. 3.10% AE 0.30%, P < 0.001, respectively) and DLD1 cells (13.50% AE 0.60% vs. 9.75% AE 0.05%, P < 0.01 and 6.55% AE 0.25% vs. 4.25% AE 0.15%, P < 0.05, respectively; Fig. 5D and E). The induction of apoptosis was further confirmed by the increased expression of cleaved caspase-3, a key apoptosis-related factor, in p75NGFR-transfected cells (Fig. 5F ). These results indicate that apoptosis may contribute to the growth inhibition of p75NGFR-transfected cells.
Correlation of methylated P75NGFR with clinicopathologic characteristics and long-term survival of patients with colorectal cancer
The correlation of the p75NGFR methylation status with clinicopathologic characteristics was evaluated in 128 patients with primary colorectal cancer. Among these patients, promoter methylation of p75NGFR was found in 65.6% (84/128), but not in the other 34.4% (44/128), of the samples. A significant correlation was found between p75NGFR methylation and both the histologic grade (P ¼ 0.014) and the preoperative serum CA19-9 levels (P ¼ 0.006), whereas no correlation was found with other indicators such as gender, age, location, pathologic stage, and preoperative serum CEA levels ( Table 2 ).
In the present study, the correlation of the p75NGFR protein expression status with OS and DFS for patients with colorectal cancer was also evaluated. The 5-year OS and DFS for all patients were 73% and 71%, respectively. The 5-year OS and DFS for patients lacking p75NGFR were significantly lower than those for patients with p75NGFR positive (64% vs. 75%, P ¼ 0.028 for OS and 61% vs. 72%, P ¼ 0.034 for DFS; Fig. 6 ). Upon univariate analysis, tumor location, N stage, T stage, M stage, TNM stage, preoperative CEA levels, and p75NGFR protein expression status were found to be prognostic factors for OS. However, only the tumor location, TNM stage, preoperative CEA levels, and p75NGFR protein expression status [HR, 1.810; 95% confidence interval (CI), 1.092-2.998; P ¼ 0.021] were independent prognostic indicators for OS by multivariate analysis (Table 3) . Compared with p75NGFR-positive patients with colorectal cancer, p75NGFR-negative patients with colorectal cancer had an increased risk of death by a factor of 1.810. Similarly, the tumor location, N stage, TNM stage, preoperative CEA levels, and p75NGFR protein expression status were found to be prognostic factors for DFS by univariate analysis. Multivariate analyses demonstrated that the loss of p75NGFR expression (HR, 1.798; 95% CI, 1.085-2.982; P ¼ 0.023) was an independent poor predictor for DFS of patients with colorectal cancer. Patients lacking p75NGFR had an increased risk of relapse by a factor of 1.798 compared with that of p75NGFR-positive patients (Table 4) . Survival analysis of patients with colorectal cancer based on p75NGFR protein expression. On the basis of the presence of p75NGFR protein expression, the patients with colorectal cancer were divided into two groups: p75NGFR (À) or p75NGFR (þ). A, the OS of patients with colorectal cancer in the p75NGFR (À) and p75NGFR (þ) groups. The 5-year OS was 64% and 75% in the p75NGFR (À) and p75NGFR (þ) groups, respectively; P ¼ 0.028. B, DFS of patients with colorectal cancer who underwent potentially curative procedures. The 5-year DFS was 61% and 72% in the p75NGFR (À) and p75NGFR (þ) groups, respectively; P ¼ 0.034.
Discussion
The initiation and progression of colorectal cancer results from the coincident effects of both genetic and epigenetic changes in normal colon epithelial cells (17) . Compared with genetic alterations, epigenetic alterations can affect a variety of genes functioning as tumor suppressors, even if they are regulating different processes (18) . For this reason, promoter methylation status has been considered an important marker to detect novel tumorsuppressor genes. We have identified p75NGFR as a hypermethylated gene in colorectal cancer tissues compared with normal tissues through a genome-wide promoter region hypermethylation screen (14) . p75NGFR is a member of the TNFR superfamily and has been shown to be a conditional tumor-suppressor gene (19) . In breast cancer and melanoma, p75NGFR acts as an oncogene, increasing cell proliferation, survival, and migration (6, (20) (21) (22) . In contrast, in prostate cancer and neuroblastoma, p75NGFR acts as a tumor-suppressor gene, inducing apoptosis and inhibiting cell proliferation and invasion (23) (24) (25) (26) (27) . Although p75NGFR is a conditional tumor suppressor in several types of cancers, the function of p75NGFR in colorectal cancer remains unclear.
In the present study, downregulation of p75NGFR by hypermethylation of CpG islands in the promoter regions was evaluated by MS-PCR and qRT-PCR. In an independent set of 38 cases, promoter methylation was detected in 60.5% of colorectal cancer tissues, whereas it was only detected in 7.9% of the corresponding adjacent nontumor tissues. Furthermore, following pharmacologic demethylation treatment, p75NGFR expression could be restored in silenced cells, suggesting that promoter methylation plays a predominant role in the regulation of p75NGFR expression in colorectal cancer. However, we cannot exclude the existence of other epigenetic mechanisms in the silencing of p75NGFR, such as histone or nucleosome remodeling. To validate our results, we completed an overview analysis from the TCGA data portal using a Firehose analysis run. This analysis identified p75NGFR as one of the significantly negatively correlated genes in colon cancer, which supports the results obtained in the present study. We further explored the correlation between the methylation status and mRNA expression of p75NGFR in other 29 cancers, with the exception of colon cancer and rectal cancer; a significantly negative correlation was also found in 22 of these cancers. Altogether, the data indicate that epigenetic silencing of p75NGFR is involved in certain types of solid cancers, including colorectal cancer. CIMP provides a unique opportunity to study the molecular mechanisms that lead to epigenetic changes in colorectal cancer as well as the contributions of these changes in the development of colorectal cancer. We analyzed the CIMP status and p75NGFR methylation in 32 patients with colorectal cancer to explore the relationship between the methylation status of p75NGFR and epigenetic changes such as chromosome instability in colorectal cancer. However, we did not observe any statistically significant association of the CIMP (À)/CIMP (þ) status with p75NGFR methylation. These results suggest that the hypermethylation of p75NGFR in colorectal cancer may be caused by other epigenetic changes, such as high expression of DNMTs.
We have demonstrated that p75NGFR could be a potential tumor-suppressor gene in colorectal cancer due to its inactivation in colorectal cancer tissues and cell lines and its expression in normal tissues. Therefore, we investigated the function of p75NGFR as a tumor suppressor in colorectal cancer. The ectopic expression of p75NGFR in silenced colorectal cancer cells transfected with the full ORF fraction of p75NGFR significantly suppressed the proliferation ability and colony formation of cancer cells. The capabilities of the cells for invasion and migration were also suppressed by the ectopic expression of p75NGFR in HT29 and DLD1 cells. Knockdown of p75NGFR by siRNA in SW480 cells significantly increased cell proliferation, invasion, and migration ability. On the basis of these results, we determined that p75NGFR functions as a tumor-suppressor gene in colorectal carcinogenesis and metastasis.
On the basis of these data, we analyzed the effects of overexpressing p75NGFR on cell apoptosis and the cell cycle in HT29 and DLD1 cells to better understand the mechanisms of the growth inhibitory effect of p75NGFR. Our results showed that the reexpression of p75NGFR significantly increased apoptosis in both HT29 and DLD1 cells. In addition, G 1 -phase arrest was detected in HT29 and DLD1 cells ectopically expressing p75NGFR. These results suggest that p75NGFR inhibits the ability of cells to proliferate by inducing apoptosis and G 1 -phase arrest, which is similar to the results observed in prostate cancer (23) .
We next investigated the clinical implications of p75NGFR methylation in colorectal cancer. In a series of 128 patients with primary colorectal cancer, we found that the methylation of p75NGFR was associated with the histologic grade (P ¼ 0.014) and preoperative serum CA19-9 levels (P ¼ 0.006), but not with other clinicopathologic characteristics. Moreover, the loss of p75NGFR protein expression was determined to be an independent prognostic factor for poor OS and DFS by multivariate regression analysis, which indicated that p75NGFR could be considered an independent potential prognostic indicator for colorectal cancer. These results are similar to what has been shown in breast cancer (20) , and they may provide further evidence for a role of p75NGFR as a tumor-suppressor gene in the initiation and progression of colorectal cancer.
In conclusion, our results show that p75NGFR is a potential tumor-suppressor gene in colorectal cancer. We found that p75NGFR expression is silenced by promoter methylation in colorectal cancer tissues and cell lines. p75NGFR contributes to the suppression of tumorigenesis by inhibiting cell proliferation, migration, and invasion ability. The inhibitory effect of p75NGFR occurs through the induction of cell apoptosis and G 1 -phase arrest. The loss of the p75NGFR protein in colorectal cancer tissues is correlated with poor OS and DFS of patients with colorectal cancer, which acts as an independent prognostic indicator in colorectal cancer.
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